When clinical data from outside Europe actually counts

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The underlying assumption is dangerous: clinical data is clinical data, regardless of where it was generated. If a device performed well in Boston or Beijing, surely it will perform well in Brussels.

Except the MDR doesn’t work that way. And neither do Notified Bodies.

What the MDR Actually Requires

Annex XIV Part A of the MDR is explicit. The clinical evaluation must be based on clinical data that is relevant to the device and its intended use. Relevance includes the target patient population, the clinical conditions treated, and the clinical environment in which the device is used.

Article 61(5) goes further. It states that clinical investigations conducted outside the EU may be accepted only if the data is adequate and the rights of subjects are equivalent to those under the MDR. But adequacy is not automatic. It must be demonstrated.

What manufacturers miss is the word “adequate.” Adequacy is not about sample size or study design alone. It includes the question: is this population, this clinical setting, this standard of care representative enough to predict outcomes in Europe?

Why Geographic Differences Matter

The human body is not identical across continents. Neither is healthcare.

Start with the obvious: patient demographics. Body mass index distributions differ between populations. So do genetic polymorphisms that affect drug metabolism, device compatibility, and healing rates. A vascular device tested only in a Northern European population may not reflect the anatomical variations seen in Southern Europe or the Middle East.

Then consider disease presentation. Diabetes prevalence and severity vary by region. So does cardiovascular disease burden. A wound care device validated in a population with low diabetes prevalence may face different performance challenges in a population where diabetes is endemic.

But the differences go beyond biology.

Standard of care varies. A surgical device used as a first-line intervention in one country may be used only after other treatments have failed in another. That difference changes the patient profile, the baseline condition, and the expected outcomes. The clinical data generated in one setting cannot simply be transferred without acknowledging that context.

Healthcare infrastructure matters too. A monitoring device that relies on wireless connectivity may perform well in a country with robust telehealth systems but face usability and compliance issues elsewhere. A device that assumes daily access to trained personnel may not reflect real-world use in more resource-limited settings within Europe.

What Notified Bodies Look For

When I review a clinical evaluation report that relies on non-European data, the first question is: did the manufacturer acknowledge the geographic origin of the data?

The second question: did they analyze whether that origin affects the validity of the conclusions?

Most reports fail at the first question. The data is cited. The studies are summarized. But there is no explicit acknowledgment that the data comes from populations outside Europe. It’s as if the manufacturer hoped no one would notice.

Others acknowledge the geography but dismiss it in a single sentence: “The patient population is comparable to the European population.” No evidence. No reasoning. Just assertion.

What reviewers want to see is a structured analysis.

First, identify the geographic origin of every major data source. Be explicit. If the pivotal clinical trial was conducted in the United States, state it. If the literature review includes predominantly Asian studies, state it.

Second, compare the study populations to the intended European population. Use demographic data. Compare disease prevalence. Compare comorbidity profiles. If differences exist, state them clearly.

Third, assess whether those differences could reasonably affect device performance or clinical outcomes. This is not speculation. It is clinical reasoning based on device mechanism, patient pathophysiology, and clinical use.

Fourth, if differences are identified, explain how you addressed them. Did you include European post-market data? Did you conduct an EU-based clinical investigation? Did you adjust claims or labeling to reflect the population in which the device was actually tested?

This is not bureaucracy. This is scientific rigor.

When Non-European Data Is Acceptable

Not all non-European data is problematic. Some device categories are less sensitive to geographic variation.

A surgical instrument with a purely mechanical action and no interaction with biological variation may have clinical data that transfers well across geographies. The anatomy is the same. The surgical technique is the same. The outcome measures are objective.

But even here, assumptions must be tested. Does the device rely on a specific surgical approach that is more common in one region? Does the indication overlap perfectly between markets, or are there differences in regulatory scope?

For devices where performance depends on patient characteristics—implants, drug-delivery systems, diagnostic devices—the burden of proof is higher. You must show that the population in which the device was tested is sufficiently similar to the European population, or that differences have been accounted for.

One approach is triangulation. If you have US clinical trial data, supplement it with European post-market surveillance data. If the two sources converge, the geographic concern diminishes. If they diverge, you have a signal that geographic factors may matter.

The Role of PMCF in Bridging the Gap

When the available clinical data comes predominantly from outside Europe, PMCF becomes essential—not optional.

PMCF is your mechanism to validate that the device performs in the European population as expected based on non-European data. It’s how you close the loop.

If your clinical evaluation report relies on US data, your PMCF plan should include European data collection. If the literature comes from Asia, your post-market surveillance should track outcomes in Europe and compare them to the published results.

This is not about generating new clinical trials for every device. It’s about structured post-market evidence generation that confirms or refines your initial clinical evaluation conclusions.

And when geographic differences do emerge in PMCF data, you update the clinical evaluation report, reassess risks, and adjust labeling or instructions for use as needed. That’s the cycle the MDR expects.

What Happens When You Ignore Geographic Validity

The consequences are predictable.

Notified Bodies issue deficiency notices. They ask for justification that was never provided. They request additional data that may not exist. The review stalls.

In some cases, they reduce the scope of the intended use to match the population in which the device was actually tested. A device intended for the general adult population becomes limited to a narrower demographic because the data only supports that narrower claim.

In other cases, the clinical evaluation is deemed insufficient, and the manufacturer is required to conduct a European clinical investigation before CE marking can proceed. This is not theoretical. I’ve seen it happen to devices that assumed US data would be enough.

The worst outcome is post-market. If the device performs differently in Europe than in the population where it was tested, you face a safety signal, possibly a field safety corrective action, and reputational damage. Geographic validity isn’t just a regulatory formality. It’s a patient safety issue.

How to Address Geographic Validity in Your CER

The solution is straightforward, but it requires discipline.

Include a dedicated section in your clinical evaluation report titled “Geographic Validity of Clinical Data.” Make it visible. Make it explicit.

In that section, list every major data source and its geographic origin. For each source, provide a brief analysis of whether the population, clinical setting, and standard of care are comparable to Europe. If they are, state why. If they are not, state what you did to address the gap.

Use references. Cite epidemiological data. Cite clinical guidelines. Show that your reasoning is based on evidence, not assumption.

If your data is predominantly non-European and you cannot yet provide European PMCF data, acknowledge this as a limitation. State explicitly that PMCF will be used to validate the findings in the European population. Then ensure your PMCF plan reflects that commitment.

This transparency does not weaken your submission. It strengthens it. It shows that you understand the regulatory expectation and that you have a plan to meet it.

Final Thought

Clinical data from outside Europe can absolutely count. But only when you demonstrate that it should.

The burden is on the manufacturer to show relevance, not on the Notified Body to assume it. And relevance is not automatic. It must be argued, supported, and confirmed through post-market data.

When manufacturers treat geographic validity as an afterthought, they create risk—regulatory risk, timeline risk, and patient risk. When they treat it as a core part of clinical evaluation, they build submissions that withstand scrutiny and devices that perform as claimed.

The question is not whether your data comes from Boston or Brussels. The question is whether you can justify why it matters—or why it doesn’t.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.